Hypothesis

Age‑associated decline of TGF‑β signaling in gut‑associated lymphoid tissue (GALT) permits autoreactive B‑cell clones to escape mucosal tolerance, enter the circulation, and seed neuroinflammation that drives brain aging. We hypothesize that simultaneous mucosal delivery of active TGF‑β and a gut‑microbiota‑derived short‑chain fatty acid (SCFA) cocktail (primarily butyrate) will synergistically restore GALT B‑cell tolerance, reduce systemic autoreactive B‑cell output, and thereby attenuate age‑related neuroinflammatory pathology more effectively than either agent alone or systemic anti‑inflammatory treatments.

Mechanistic Rationale

• TGF‑β in GALT drives deletion of self‑reactive B cells via a Smad‑dependent pathway that is distinct from bone‑marrow central tolerance [1]. Age‑related loss of this signal lowers the threshold for clonal escape [3].
• Butyrate (and other SCFAs) enhances colonic Treg differentiation and increases local TGF‑β production through HDAC inhibition and GPR109A signaling [5]. Moreover, butyrate promotes IgA class switching and supports the gut barrier, limiting translocation of microbial products that further aggravate GALT inflammation.
• Synergy: Exogenous TGF‑β provides the immediate tolerogenic cue, while butyrate sustains an endogenous TGF‑β‑rich microenvironment and improves mucosal integrity, together reversing the age‑related defect in negative selection.
• Predicted downstream effects: (1) Decreased frequency of autoreactive IgG+ B cells in peripheral blood and spleen; (2) Reduced clonal expansion of CNS‑infiltrating lymphocytes observed in aged mice [6]; (3) Lower CSF levels of pro‑inflammatory cytokines (IL‑6, TNF‑α, CCL2); (4) Preservation of hippocampal synaptic markers and improved performance in spatial memory tasks (e.g., Morris water maze).

Experimental Design (Testable & Falsifiable)

1. Animal model: C57BL/6 mice, 20‑month‑old (aged) vs. 3‑month‑old (young) controls.
2. Intervention groups (n=12 per group):
   • Vehicle (control)
   • Oral TGF‑β (1 µg/day, encapsulated to resist gastric degradation)
   • Oral butyrate (200 mM in drinking water)
   • Combined TGF‑β + butyrate (same doses)
   • Positive control: systemic anti‑CD20 depletion (to compare magnitude of B‑cell reduction).
3. Duration: 12 weeks.
4. Readouts:
   • Flow cytometry of Peyer’s patches and mesenteric lymph nodes for Annexin V+/self‑reactive B cells (using fluorescently labeled self‑antigen tetramers).
   • Serum autoantibody profiling (antinuclear antibodies, anti‑dsDNA ELISA).
   • Single‑cell VDJ repertoire of blood and spleen to quantify clonal expansion of autoreactive lineages.
   • Immunohistochemistry of brain sections for Iba1+ microglia and infiltrating CD19+ B cells.
   • CSF cytokine multiplex assay.
   • Behavioral battery: Y‑maze spontaneous alternation, novel object recognition, and Morris water maze.
5. Statistical analysis: Two‑way ANOVA (treatment × age) with post‑hoc Tukey; significance set at p<0.05.

Falsifiability Criteria

• If the combined TGF‑β + butyrate group does not show a statistically significant reduction (≥30 %) in autoreactive B‑cell frequency compared with vehicle, the hypothesis is falsified.
• If neuroinflammatory markers (CSF cytokines, brain Iba1+ density) and cognitive performance are unchanged despite B‑cell tolerance restoration, the causal link between GALT‑derived autoreactive B cells and brain aging would be questioned.
• Conversely, if either monotherapy matches or exceeds the combined effect, the purported synergy would be refuted.

Potential Impact

Demonstrating that mucosal immune re‑programming outperforms brain‑centric strategies would shift the longevity intervention stack from top‑down (neuroprotective drugs, cognitive training) to bottom‑up (gut‑targeted tolerance therapies). This approach could be translated to humans via enteric‑coated TGF‑β analogues and fermented‑fiber diets, offering a safe, microbiome‑based avenue to delay neuroinflammatory aging.